Core Insights - Shares of Xenon Pharmaceuticals (XENE) have increased by approximately 20% over the past three months, primarily due to positive top-line data from the X-TOLE2 study evaluating azetukalner for focal onset seizures (FOS) [1][6] Group 1: Clinical Development - Azetukalner is being evaluated in late-stage studies for the treatment of FOS, with two identical phase III studies, X-TOLE2 and X-TOLE3, assessing 15 mg or 25 mg doses administered with food as an adjunctive treatment [2][4] - The X-TOLE2 study met its primary endpoint, demonstrating a median percent change in monthly FOS frequency from baseline to week 12 for both doses compared to placebo [3] - Azetukalner's clinical profile is differentiated from existing antiseizure therapies, featuring no titration requirement, convenient once-daily dosing, and minimal risk of drug-drug interactions [3] Group 2: Regulatory and Market Outlook - Xenon plans to submit a new drug application to the FDA for azetukalner in Q3 2026, with management highlighting the favorable safety profile and ease of use as key factors for its potential as a preferred treatment for uncontrolled seizures [4] - The ongoing phase III X-TOLE3 study is expected to support regulatory filings in international markets, enhancing the global commercial opportunity for azetukalner [5] Group 3: Broader Pipeline and Future Studies - Azetukalner is also being developed for other neurological disorders, including major depressive disorder (MDD) and bipolar depression (BPD), with top-line data from the X-NOVA2 study expected in the first half of 2027 [7] - The company is conducting a phase III X-ACKT study for azetukalner in primary generalized tonic-clonic seizures, which is currently enrolling patients [8] - Xenon has initiated early-stage studies for other pipeline assets, including XEN1120 and XEN1701, targeting Kv7 and Nav1.7 for various therapeutic indications [9]

Market Overview - The overall market is facing consistent pressure, primarily due to higher-than-expected inflation data and adjustments in the labor market [2][3] - The short end of the yield curve has seen significant increases, particularly the 2-year yield, indicating a shift in market sentiment regarding Federal Reserve actions [2][3] - Geopolitical tensions, especially in the Middle East, are contributing to market uncertainty, particularly affecting energy and shipping sectors [3] Oracle - Oracle's stock has seen a significant pullback of approximately 21% year-to-date and a 55% decline from its recent highs following earnings reports [5][6] - There is a belief that Oracle may have temporarily bottomed, with support levels around $155 to $160, suggesting potential for upside if market stability is achieved [7][8] - Technical analysis indicates a bearish trend, with caution advised despite signs of a possible short-term bottom [10][12] Johnson & Johnson - Johnson & Johnson has performed relatively well, up about 14% this year, despite a 6% pullback from recent highs [19][20] - The stock is viewed as defensive, with a potential for building off current levels, and a risk reversal strategy is suggested to capture further upside [18][19] - Technical indicators show a constructive chart, but there are concerns about weakening price momentum and potential breakdowns below key support levels [22][24] Starbucks - Starbucks has been the strongest performer this year, but there are mixed opinions regarding its costly turnaround strategy [25][27] - The stock is currently positioned for potential downside, with a strategy to buy puts to capture further weakness while having the opportunity to acquire shares at lower levels [28][31] - Technical analysis indicates defined resistance around $100 to $104 and support near $80, with recent trading behavior resembling that of a utility stock rather than a growth company [33][34]

Core Insights - The Danish drugmaker received accelerated approval for a new treatment based on the results of its Step Up trial, which demonstrated a mean weight loss of 20.7% for participants with obesity [1] Company Summary - The accelerated approval indicates a significant advancement in the company's product pipeline, potentially enhancing its market position in the obesity treatment sector [1] Industry Summary - The results from the Step Up trial highlight the growing focus on effective obesity treatments within the pharmaceutical industry, reflecting an increasing demand for innovative solutions to address obesity-related health issues [1]

Core Viewpoint - The FDA has approved a higher dose version of Novo Nordisk's weight loss injection Wegovy, which is aimed at regaining market share from Eli Lilly's obesity drug Zepbound, known for its higher efficacy in promoting weight loss [1][2]. Group 1: Product Details - Novo Nordisk plans to launch the 7.2-milligram dose of Wegovy in April, positioning it to compete more effectively against Zepbound [2]. - In clinical trials, the high-dose Wegovy resulted in an average weight loss of 20.7% after 72 weeks, compared to approximately 15% for the standard 2.4-milligram dose [3]. - A separate phase three trial showed that high-dose Wegovy led to an average weight loss of 14.1% in patients with obesity and Type 2 diabetes [5]. Group 2: Competitive Landscape - Zepbound has become the preferred obesity medication among prescribers and patients, solidifying Eli Lilly's dominant position in the market despite entering the U.S. market later than Wegovy [3]. - The introduction of the higher dose Wegovy is expected to enhance competition and provide patients with more options for achieving weight loss targets [4]. Group 3: Regulatory Context - The approval of high-dose Wegovy marks the first instance of a GLP-1 treatment being approved under the FDA's new national priority voucher plan, which aims to expedite drug review times [6].

Group 1 - Reviva Pharmaceuticals is selling 6,666,667 common shares at $1.50 each, raising over $10 million for research and development, including the RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia [2] - The stock is underperforming the Healthcare sector, down 55.61% compared to the sector's slight decline of 0.08%, indicating stock-specific issues rather than a broader sector decline [3] - Over the past 30 days, the Healthcare sector has decreased by 6.60%, while Reviva's stock decline is more pronounced, suggesting it is viewed as a higher-risk investment within the sector [4] Group 2 - Reviva Pharmaceuticals focuses on late-stage pharmaceutical development, targeting therapies for central nervous system, inflammatory, and cardiometabolic diseases [5] - The company's pipeline includes two main candidates: Brilaroxazine (RP5063) for neuropsychiatric conditions and RP1208, with the stock being sensitive to clinical progress and funding expectations [6] - Reviva is set to report earnings on March 30, 2026, with an estimated EPS of $-1.04, improving from $-3.00 year-over-year [7][8]

Financial Performance - Achieved record annual revenue of $41.7 million, driven by a 10% increase in Ameluz unit volumes and refined commercial targeting [5] - Improved gross margin profile significantly by replacing a 25-35% transfer pricing model with a 12-15% royalty-based earn-out structure [5] - Expects full-year 2026 gross profit margins to stabilize between 80% and 85% as the new cost structure applies to all sales volumes [5][7] Strategic Initiatives - Transformed the corporate structure by acquiring all U.S. rights, patents, and manufacturing contracts for Ameluz and RhodoLED from the former parent company [5] - Optimized sales operations by implementing a data-driven targeting approach and an inside sales pilot to capture previously underserved smaller accounts [5] - Divested the Xepi antibiotic cream license for $3 million in initial proceeds, with potential milestones up to $7 million to focus on core PDT assets [5] Clinical Development - Anticipates a PDUFA target action date of September 28, 2026, for the potential approval of Ameluz in treating superficial basal cell carcinoma [5] - Plans to file a supplemental NDA in 2026 to expand the Ameluz label for actinic keratosis on the extremities, neck, and trunk following positive Phase III results [5] - Intends to discuss the design of a Phase III program for moderate to severe acne vulgaris with the FDA in 2026 based on successful Phase II data [5] Operational Changes - Transitioned to full regulatory control in the U.S. following the formal FDA transfer of the NDA and IND in December 2025 [6] - Reduced customer churn to the lowest level since 2021 while successfully opening over 150 new accounts during the fiscal year [5] - Noted that legal expenses increased by $6.0 million in 2025 primarily due to ongoing patent litigation and defense costs [5]

Novo Nordisk won approval to sell a high-dose version of its blockbuster Wegovy obesity shot in the US, allowing it to offer weight loss closer to that of rival Eli Lilly's competing shot Zepbound https://t.co/pUCnYjWVYd ...

Core Insights - The FDA has approved Novo Nordisk's new higher dose of Wegovy® HD (semaglutide) injection 7.2 mg, which has shown significant weight loss in adults with obesity, particularly in the STEP UP trial [1][2] - Wegovy® HD is positioned as a superior weight loss medication compared to other GLP-1 medications, with additional cardiovascular benefits for patients with known heart disease [1][2] Summary by Sections FDA Approval and Clinical Profile - The approval of Wegovy® HD is based on the STEP UP trial, which demonstrated an average weight reduction of approximately 21% at 72 weeks for those who remained on treatment [1][2] - The previous highest approved dose was 2.4 mg, which also aimed to reduce the risk of major cardiovascular events in adults with obesity or overweight [1][2] STEP UP Trial Results - In the STEP UP trial, about one in three participants taking Wegovy® HD achieved a weight loss of 25% or more [2] - The average weight loss for Wegovy® HD was around 21% if all patients stayed on treatment, compared to 18% for the 2.4 mg dose [2][3] - The trial included 1,407 adults with a BMI of 30 kg/m² or greater, without diabetes, and lasted for 72 weeks [6] Adverse Reactions - Common adverse reactions reported with Wegovy® HD included nausea, vomiting, dysesthesia, and abdominal pain, with dysesthesia occurring at a higher rate compared to the 2.4 mg dose and placebo [4][6] - The incidence of altered skin sensations was notably higher in the Wegovy® HD group (22%) compared to the 2.4 mg group (6%) and placebo (0.3%) [4][6] Availability and Access - Wegovy® HD is set to be available in April 2026 through over 70,000 pharmacies in the US, including major chains like CVS and Costco, as well as select telehealth providers [4] - Novo Nordisk will provide information on coverage and savings options for eligible patients to help reduce out-of-pocket costs [4] Company Background - Novo Nordisk has over 100 years of experience in developing innovative medicines for chronic diseases, including diabetes and obesity [15] - The company emphasizes a long-term focus on responsible business practices and aims to improve health outcomes for patients with obesity [15]

Core Viewpoint - The Fidelity Enhanced Large Cap Growth ETF (FELG) is down 7.77% year-to-date, similar to the Vanguard Growth ETF (VUG) at 7.76%, but FELG employs a quantitative model that allows it to shift away from overvalued tech stocks, while VUG, as a passive index fund, lacks this mechanism [1][6][10]. Group 1: Performance Analysis - FELG and VUG have both experienced significant declines this year, with VUG dropping from approximately $488 to around $450 per share, reflecting a 7.76% loss [5][6]. - The Fidelity Nasdaq Composite Index ETF (ONEQ) has fared slightly better, down 4.38% year-to-date, due to its broader exposure across over 700 Nasdaq-listed securities [5][6]. Group 2: Interest Rate Impact - The trajectory of interest rates, particularly the 10-year Treasury yield, is a primary driver of growth stock performance, with the yield rising from 3.97% in late February to 4.20% as of March 17, 2026 [2][8]. - Growth stocks are sensitive to interest rate changes because their valuations are heavily influenced by future earnings, which are discounted more when rates are high [7]. Group 3: Structural Differences - FELG is not a passive index fund; it utilizes a quantitative process to favor companies with improving fundamentals, contrasting with passive funds like VUG and ONEQ that do not adjust exposure during market corrections [10][12]. - FELG's top holdings include significant positions in mega-cap tech stocks, but it also includes healthcare stocks like Eli Lilly, which may provide a different recovery profile if tech continues to lag [11]. Group 4: Future Outlook - If the 10-year Treasury yield stabilizes or decreases, and the Federal Reserve signals further rate cuts, FELG's quantitative model is designed to rotate towards fundamentally improving companies, potentially leading to a different recovery trajectory compared to passive peers [14]. - The VIX index, which peaked at 29.49 on March 6 and has since decreased to 22.37, indicates that while fear is subsiding, volatility compression may precede recoveries in growth-oriented funds [13].

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Atom Therapeutics Co., Ltd. 杭州新元素藥業股份有限公司 (the "Company") (A joint stock company established in the People's Republ ...